Discover

ABT
Abbott Laboratories
107.07
1 x 107.06
2 x 107.07
bid
ask
+
1.37
1.30%
03:39 PM
timesize
Ytd-14.54%
1y-15.88%
106.43
day range
109.33
82.56
52 week range
136.62
Open107.85Prev Close105.70Low106.43High109.33Mkt Cap182.90B
Vol4.05MAvg Vol13.13MEPS5.21P/E20.29Forward P/E18.69
Beta0.61Short Ratio1.67Inst. Own82.52%Dividend2.52Div Yield2.39
Ex Div Date07-15Earning07-1650-d Avg93.30200-d Avg108.351yr Est119.13
Earning
DateForEstimateReportedSurprisesurprise %
2026-10-212026-091.42N/AN/AN/A
2026-07-162026-061.281.310.032.34%
2026-04-162026-031.141.150.010.88%
2026-01-222025-121.51.5N/AN/A
2025-10-152025-091.31.3N/AN/A
2025-07-172025-061.261.26N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-06Evercore ISI GroupUpgradeOutperformOutperform
2026-07-01BairdUpgradeOutperform
2026-06-22Piper SandlerUpgradeOverweightOverweight
2026-04-27BTIGUpgradeBuyBuy
2026-04-20BarclaysUpgradeOverweightOverweight
2026-04-17Piper SandlerUpgradeOverweightOverweight
Profile
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Insider Holder
DateNameRelationQuantityDescription
2025-02-24ALLEN HUBERT L.Officer200.28KStock Award(Grant)
2026-04-23CONROY KEVIN TDirector133.74KStock Award(Grant)
2026-02-23EARNHARDT LISA DOfficer98.98KStock Award(Grant)
2026-02-23FORD ROBERT B.Chief Executive Officer552.97KStock Award(Grant)
2026-03-01MORELAND MARY KOfficer116.14KSale
2026-03-01MORRONE LOUIS HOfficer76.86KSale
Institution Ownership
Report DateOrganizationPositionValuePercentage
2025-12-30Vanguard Group Inc175.56M0.0010.08%
2026-03-30BlackRock Inc145.69M0.008.36%
2026-03-30Vanguard Capital Management, LLC112.95M0.006.48%
2026-03-30State Street Corp79.58M0.004.57%
2026-03-30Capital Research Global Investors49.78M0.002.86%
2026-03-30Vanguard Portfolio Management, LLC47.94M0.002.75%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Vanguard Total Stock Mkt Idx Inv55.31M0.003.18%
2026-06-29Vanguard 500 Index Investor45.25M0.002.60%
2026-06-29Schwab US Dividend Equity ETF™44.24M0.002.54%
2026-06-29iShares Core S&P 500 ETF24.04M0.001.38%
2026-05-30Fidelity 500 Index22.25M0.001.28%
2026-06-29State Street® SPDR® S&P 500® ETF21.05M0.001.21%
Dividend
DividendDate
0.632026-07-15
0.632026-04-15
0.632026-01-15
0.592025-10-15
0.592025-07-15
0.592025-04-15
Split
SplitDate
10000 : 47982013-01-02
2.0842 : 12013-01-01
10000 : 93562004-05-03
1.06883 : 12004-05-02
2 : 11998-06-01
2 : 11992-06-01